Clinical Trial: Immunogenicity and Safety of Respiratory Syncytial Virus Vaccine in Lung Transplant Recipients

U.S., Oct. 27 -- ClinicalTrials.gov registry received information related to the study (NCT07895394) titled 'Immunogenicity and Safety of Respiratory Syncytial Virus Vaccine in Lung Transplant Recipients' on Oct. 12.

Brief Summary: The purpose of this study is to compare the immunogenicity and safety of respiratory syncytial virus (RSV) vaccination between lung transplant recipients and immunocompetent adults and to provide evidence to guide RSV vaccination in lung transplant recipients.

Study Start Date: Oct., 2026

Study Type: INTERVENTIONAL

Condition: Vaccination Respiratory Syncytial Virus (RSV) Lung Transplant Recipient

Intervention: BIOLOGICAL: RSVPreF3 vaccination

One dose of RSVPreF3 (Arexvy(R)) vaccine

Recruitment Status: R...